Full history for every metric is available with a Kvantra account
Destiny Pharma plc (DEST.L)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Operating profit | £m | -7 | -7 | |||||
| Net profit | £m | -5 | -5 | -5 | -5 | -7 | -6 | -6 |
| EPS reported | £ | -0.06 | -0.06 | |||||
| Operating cashflow per share | £ | -0.06 | -0.06 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.06 | -0.06 | |||||
| Free cash flow | £m | -5 | -5 | |||||
| Net debt | £m | -6 | -6 | |||||
| Book value equity | £m | 9 | 9 | |||||
| Book value per share | £ | 0.10 | 0.10 | |||||
| Number of shares | m | 90.67 | 95.27 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 6.91 | 0.31 | |||||
| P/S LTM | x | 76.33 | 3.46 | |||||
| P/FCF LTM | x | -12.05 | -0.52 | |||||
| EV/EBITDA LTM | x | -8.70 | 0.52 | |||||
| EV/Sales LTM | x | 68.65 | -4.22 | |||||
| Earnings Yield LTM | % | -8.91% | -207.97% | |||||
| FCF Yield | % | -8.30% | -190.57% | |||||
| Quality | ||||||||
| ROE | % | -61.56% | -67.28% | |||||
| ROIC | % | -62.74% | -62.74% | |||||
| Operating margin | % | -790.08% | -790.08% | |||||
| Gross margin | % | 99.25% | 99.25% | |||||
| FCF/Sales | % | -633.22% | -633.22% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +438.22% | +438.22% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.97 | 0.97 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -10.06% | -222.15% | |||||
| Net debt/Equity | x | -0.69 | -0.69 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Destiny Pharma plc (DEST.L)
Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free